Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP3 | P05413 | 2/20 | 0.47 |
| ▸ | FABP4 | P15090 | 2/20 | 0.47 |
| ▸ | FABP5 | Q01469 | 2/20 | 0.47 |
| ▸ | ACLY | P53396 | 3/20 | 0.47 |
| ▸ | HTR6 | P50406 | 9/20 | 0.45 |
| ▸ | AGTR1 | P30556 | 2/20 | 0.44 |
| ▸ | GBA1 | P04062 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | FABP2 | P12104 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6420752 | 0.85 | AGTR1 (0.50) | FABP3FABP4FABP5ACLYHTR6 | |
| SCHEMBL3557485 | 0.82 | AGTR1 (0.58) | FABP3FABP4FABP5ACLYHTR6 | |
| SCHEMBL6424798 | 0.82 | ACLY (0.45) | FABP3FABP4FABP5ACLYHTR6 | |
| SCHEMBL14732435 | 0.80 | FABP3 (0.58) | FABP3FABP4FABP5HTR6FABP2 | |
| SCHEMBL3556363 | 0.80 | HTR6 (0.49) | FABP3FABP4FABP5ACLYHTR6 | |
| SCHEMBL3562373 | 0.75 | HTR6 (0.43) | HTR6AGTR1GBA1 | |
| SCHEMBL3562443 | 0.73 | ACLY (0.50) | ACLYHTR6AGTR1 | |
| SCHEMBL14719615 | 0.73 | FABP3 (0.42) | FABP3FABP4FABP5HTR6GBA1 | |
| SCHEMBL3563939 | 0.70 | ACLY (0.62) | ACLYKMT2A | |
| SCHEMBL14732434 | 0.69 | FABP3 (0.49) | FABP3FABP4FABP5HTR6GBA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1567492-B1 | N-ARYLSULFONYL-3-AMINOALKOXYINDOLES | SUVEN LIFE SCIENCES LTD (IN) | 2013-05-22 | — | — | EP | disclosed |
| US-7718690-B2 | N-arylsulfonyl-3-aminoalkoxyindoles | RAMAKRISHNA VENKATA SATYA NIROGI | 2010-05-18 | — | — | US | disclosed |
| US-20090131507-A1 | N-arylsulfonyl-3-aminoalkoxyindoles | SUVEN LIFE SCIENCES LIMITED (IN) | 2009-05-21 | — | — | US | disclosed |
| EP-1567492-A2 | N-ARYLSULFONYL-3-AMINOALKOXYINDOLES | Suven Life Sciences Limited (IN) | 2005-08-31 | — | — | EP | disclosed |
| WO-2004048328-A2 | N-ARYLSULFONYL-3-AMINOALKOXYINDOLES | SUVEN LIFE SCIENCES LIMITED (IN) | 2004-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131507-A1 | N-arylsulfonyl-3-aminoalkoxyindoles | HTR3C, HTR3A, AANAT | FABP3 1742/4885FABP4 4163/4885FABP5 4064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.